Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Alogliptin and glimepiride

Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.

DRUG

Alogliptin and glimepiride

Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.

DRUG

Glimepiride

Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY